ReviewCardiovascular intervention and therapeutics2022
CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022.
Review in Cardiovascular intervention and therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 3 syntheses or guidelines pooled it, 124 citations in OpenAlex.
- β-blocker and clinical outcomes in patients after myocardial infarction: a systematic review and meta-analysis.European journal of clinical pharmacology · 2025Pooled it
- CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2024.Cardiovascular intervention and therapeutics · 2024Guideline
- Association between controlling nutritional status score and the prognosis of patients with acute myocardial infarction: a systematic review and meta-analysis.Frontiers in nutrition · 2024Pooled it
- Single catheter primary percutaneous coronary intervention method in patients with ST-elevation myocardial infarction: the SPEEDY-PCI study.Cardiovascular intervention and therapeutics · 2025Trial
- Combined Prognostic Value of Triglyceride-Glucose Index and Bilirubin in Drug-Eluting Stent Restenosis: From Clinical Risk Stratification to Exploratory Vascular-Cell Findings.Cardiovascular drugs and therapy · 2026Article
- Tailoring implementation strategies for acute coronary syndrome quality improvement program at primary care level in east, west, and central China.Health policy and planning · 2026Article
- Slick K+ channels contribute to cardiac remodeling, fibrosis, and dysfunction in postinfarction hearts.JCI insight · 2026Article
- Anemia and long-term outcomes after second-generation drug-eluting stent implantation: a retrospective cohort study of mortality and clinical restenosis.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2026Article
- CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2026.Cardiovascular intervention and therapeutics · 2026Article
- Article
- Sub-analysis of perfusion balloon predilatation with intracoronary nicorandil vs. distal protection for acute coronary syndrome: A comparative evaluation.Fujita medical journal · 2026Article
- Molecular mechanisms of suxiao jiuxin pills in ameliorating post-acute myocardial infarction inflammatory response: a combined network pharmacology, Mendelian randomization, and experimental validation study.Frontiers in cardiovascular medicine · 2026Article
- Development of a Cardiac Catheterization Laboratory Nursing Program Targeting Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction: A Delphi Study.Journal of multidisciplinary healthcare · 2026Article
- Alert-associated cardiovascular events in Gulf civilian populations: emerging risks and surveillance opportunities.Frontiers in public health · 2026Article
- Advances in Technology and Technique in Percutaneous Coronary Intervention: A Clinical Review.Internal medicine (Tokyo, Japan) · 2026Review
- Factors that impact in-hospital mortality due to STEMI versus NSTEMI in a first percutaneous coronary intervention: survival analysis.Archivos de cardiologia de Mexico · 2026Article
- Pharmacological Evaluation of Ticagrelor and Aspirin Versus Clopidogrel and Aspirin Pretreatment on Infarct Artery Flow in Patients with Acute STEMI.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Effectiveness and Safety of CENTUM™, an Everolimus-Eluting Stent, in Patients With Coronary Artery Disease: A Prospective Multi-Center Observational Study.Korean circulation journal · 2025Article
- Prediction of adverse left ventricular remodeling by culprit lesion features in patients with LAD-related myocardial infarction.Scientific reports · 2025Article
- Detecting a potential causal relationship between plasma metabolites and myocardial infarction using bidirectional and two-step Mendelian randomization.Scientific reports · 2025Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
55 authors at 20 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary Percutaneous Coronary Intervention (PCI) has significantly contributed to reducing the mortality of patients with ST-segment elevation myocardial infarction (STEMI) even in cardiogenic shock and is now the standard of care in most of Japanese institutions. The Task Force on Primary PCI of the Japanese Association of Cardiovascular Interventional and Therapeutics (CVIT) society proposed an expert consensus document for the management of acute myocardial infarction (AMI) focusing on procedural aspects of primary PCI in 2018. Updated guidelines for the management of AMI were published by the European Society of Cardiology (ESC) in 2017 and 2020. Major changes in the guidelines for STEMI patients included: (1) radial access and drug-eluting stents (DES) over bare-metal stents (BMS) were recommended as a Class I indication, (2) complete revascularization before hospital discharge (either immediate or staged) is now considered as Class IIa recommendation. In 2020, updated guidelines for Non-ST-Elevation Myocardial Infarction (NSTEMI) patients, the followings were changed: (1) an early invasive strategy within 24 h is recommended in patients with NSTEMI as a Class I indication, (2) complete revascularization in NSTEMI patients without cardiogenic shock is considered as Class IIa recommendation, and (3) in patients with atrial fibrillation following a short period of triple antithrombotic therapy, dual antithrombotic therapy (e.g., DOAC and single oral antiplatelet agent preferably clopidogrel) is recommended, with discontinuation of the antiplatelet agent after 6 to 12 months. Furthermore, an aspirin-free strategy after PCI has been investigated in several trials those have started to show the safety and efficacy. The Task Force on Primary PCI of the CVIT group has now proposed the updated expert consensus document for the management of AMI focusing on procedural aspects of primary PCI in 2022 version.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.